| Project/Area Number |
18591459
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
KONO Koji University of Yamanashi, Department of Research Interdisciplinary graduate school of medicine and engineering, Associate Professor (40283204)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGAI Hidemitsu University of Yamanashi, Hospital, Research Associate (10345712)
KAWAGUCHI Yoshihiko University of Yamanashi, Hospital, Medical Official (80402048)
赤池 英憲 山梨大学, 医学部附属病院, シニアレジデント (00402032)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,910,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2006: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | Cancer vaccination / Esophageal cancer / 樹状細胞 |
|---|
| Research Abstract |
In the present project, we performed cancer vaccination clinical trial as an adjuvant setting after chemo-radiation therapy (CRT) for esophageal cancer by using immune-dominant peptides derived from HER-2 and MAGE3. The primary aim of the study is evaluation of safety and immunological effect. At present, 8 patients were enrolled into the present study and received cancer vaccination with peptide-pulsed mature DCs biweekly for 5 rounds in the combination with TS-1. There was no severe side effect and the treatment was well-tolerated. As an immunological monitoring by Elispot assay established by us, specific immune response for the peptide were observed in 4 out of 8 patients received cancer vaccination. As clinical effects, 4 out of 8 patients preserved CR and PR after CRT, while 4 out of patients revealed recurrence of tumor (PD). There was no significant correlation between positive immunological response and clinical outcome.
|
